Phase 2 Trial of Chidamide-Lenalidomide-Dexamethasone(CRD) Regimen in R/R MM

Multiple Myeloma Clinical Trial

Official title:

Chindamide in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma, a Phase II Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03605056
• Other study ID #: SHZS-MM001
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: July 31, 2018
• Est. completion date: July 31, 2022

Study information

• Verified date: July 2018
• Source: Shanghai Zhongshan Hospital
• Contact: Zheng Wei, MD
• Phone: 00862164041990
• Email: wei.zheng[@]zs-hospital.sh.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and effectiveness of combination of Chidamide-Lenalidomine-Dexamethasone in relapsed or refractory multiple myeloma patients

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 25
• Est. completion date: July 31, 2022
• Est. primary completion date: July 31, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female patient = age 18 years

• Patient is able to understand and has given voluntary written informed consent before performance of any study-related procedures not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care

• Patient has been previously diagnosed with MM based on standard International Myeloma Working Group (IMWG) criteria and currently requires treatment.

• Patient must have received at least one previous line of therapy for multiple myeloma including bortezomib

• Patient must have demonstrated disease progression on or within 60 days of completion of the last therapy. Patient has measurable disease defined as at least one of the following:

• Serum M protein = 0.5 g/dL (=5 g/L)

• Urine M protein =200 mg/24 hours

• Serum free light chain (FLC) assay: Involved FLC assay =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)

• Eastern Cooperative Oncology Group (ECOG) performance status =2

• Negative serum or urine pregnancy test for women of child-bearing potential

• Screening Laboratory parameters:

• Absolute neutrophil count (ANC) = 1,500 cells/dL (1.5 x 10^9/L). Granulocyte colony-stimulating factor (GCSF) is not permitted during screening to meet eligibility criteria and within 14 days of initiation of therapy

• Platelet count = 70,000 cells/dL (70 x 10^9/L) Platelet transfusion is not permitted during screening to meet eligibility criteria and within 14 days of initiation of therapy

• Hemoglobin = 8.0 g/dl ( red blood cell (RBC) transfusions are permitted during the screening period)

• Total Bilirubin = 1.5 X upper limit of normal (ULN) ; Aspartate transaminase (AST, or SGOT) and alanine transaminase (ALT, or SGPT) = 2.5x ULN Estimated creatinine clearance by Cockcroft-Gault formula = 50 mL/min

Exclusion Criteria:

• Diagnosed or treated for another malignancy within 3 years prior to enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, an in situ malignancy, or low risk prostate cancer after curative therapy.

• Received any investigational drug within 14 days or 5 half-lives of the investigational drug, whichever is longer.

• Prior anti-cancer therapy within 14 days.

• Patient has any Grade 3 or > unresolved peripheral neuropathy from previous treatment.

• Patient is human immunodeficiency virus (HIV) positive,.

• Patient is Hepatitis B Surface antigen-positive or HBV-DNA copies > 10^3/ml

• Patient has active hepatitis C infection.

• Hypersensitivity to any of the required concomitant drugs or supportive treatments, including hypersensitivity to antiviral drugs

• Known history of allergy to 2 or > drugs or any component of regimen

• Any clinically significant, uncontrolled medical conditions that, in the treating Investigator's opinion, would impose excessive risk to the patient or may interfere with compliance or interpretation of the study results. Uncontrolled intercurrent illness may include, but is not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, clinically significant cardiac arrhythmia, or psychiatric illness/social situations as determined by treating investigator that would limit compliance with study requirements.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell

Intervention

Drug:
• chidamide
20 mg/d, will be administered orally, on Days 1, 4, 8, 11 of each 21 day cycle
• lenalidomide
25 mg/d, will be administered orally on Days 1-14 each 21 day cycle
• dexamethasone
40mg weekly, will be administered orally or intravenously

Locations

Country	Name	City	State
China	180 Fenglin Road	Shanghai	Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Peng Liu	Chipscreen Biosciences, Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate	according to IMWG criteria, including the rate of complete remission (CR), very good partial remission (VGPR) and partial remission (PR)	2 years
Secondary	Number of participants with treatment-related adverse events	as assessed by CTCAE v4.0	2 years
Secondary	Overall Survival Rate	The percentage of people in the study group who are still alive 2 years after the start of treatment	2 years